Aclarion, Inc. filings document material events and governance for a commercial-stage healthcare technology issuer with Nasdaq-listed common stock and warrants. Recent Form 8-K reports cover capital actions such as a share repurchase authorization, executive finance leadership transition, employment agreement terms and Regulation FD communications.
The company's regulatory record also includes annual meeting and stockholder-vote disclosures, director elections, emerging growth company status and common stock information. These filings frame Aclarion's public reporting around its healthcare technology business, governance controls, officer appointments and capital-structure actions.
Aclarion, Inc. reported a larger net loss for the quarter ended March 31, 2026, while significantly strengthening its cash position through new equity financing. Revenue rose modestly to $21,140 from $18,991, driven mainly by more Nociscan reports sold in the U.K.
Operating expenses nearly doubled to $2.99 million, reflecting higher sales and marketing spending around the CLARITY Trial, greater research and development, and increased general and administrative costs such as investor relations and Delaware franchise taxes. Net loss widened to $2.85 million from $2.04 million, or $(1.34) per share.
Cash, cash equivalents and restricted cash increased to $19.03 million, supported by a January 2026 registered direct offering of common stock and pre-funded warrants that generated roughly $10.4 million in gross proceeds. The company expects its current cash to fund operations into the second half of 2027. Subsequent to quarter-end, the board approved a $2.5 million share repurchase program and adopted a stockholder rights agreement intended to discourage hostile accumulations of its stock.
Aclarion, Inc. reported a larger net loss for the quarter ended March 31, 2026, while significantly strengthening its cash position through new equity financing. Revenue rose modestly to $21,140 from $18,991, driven mainly by more Nociscan reports sold in the U.K.
Operating expenses nearly doubled to $2.99 million, reflecting higher sales and marketing spending around the CLARITY Trial, greater research and development, and increased general and administrative costs such as investor relations and Delaware franchise taxes. Net loss widened to $2.85 million from $2.04 million, or $(1.34) per share.
Cash, cash equivalents and restricted cash increased to $19.03 million, supported by a January 2026 registered direct offering of common stock and pre-funded warrants that generated roughly $10.4 million in gross proceeds. The company expects its current cash to fund operations into the second half of 2027. Subsequent to quarter-end, the board approved a $2.5 million share repurchase program and adopted a stockholder rights agreement intended to discourage hostile accumulations of its stock.
Aclarion, Inc. director Scott Breidbart made an open-market purchase of Common Stock. On May 12, 2026, he bought 5,664 shares at a price of $3.18 per share in a public market transaction. Following this trade, his directly held position stands at 5,664 shares.
Aclarion, Inc. director Scott Breidbart made an open-market purchase of Common Stock. On May 12, 2026, he bought 5,664 shares at a price of $3.18 per share in a public market transaction. Following this trade, his directly held position stands at 5,664 shares.
Aclarion, Inc. director Neal David K completed an open-market purchase of 2,500 shares of Aclarion common stock on May 11, 2026. The shares were bought at an average price of $3.10 per share. Following this transaction, he directly holds 2,502 common shares of Aclarion.
Aclarion, Inc. director Neal David K completed an open-market purchase of 2,500 shares of Aclarion common stock on May 11, 2026. The shares were bought at an average price of $3.10 per share. Following this transaction, he directly holds 2,502 common shares of Aclarion.
Aclarion, Inc. director and CEO Brent Ness reported an open-market purchase of company stock. He bought 6,289 shares of Common Stock on the public market at a price of $3.18 per share. After this transaction, he directly owns 6,300 shares of Aclarion Common Stock.
Aclarion, Inc. director and CEO Brent Ness reported an open-market purchase of company stock. He bought 6,289 shares of Common Stock on the public market at a price of $3.18 per share. After this transaction, he directly owns 6,300 shares of Aclarion Common Stock.
Aclarion, Inc. director William Wesemann bought shares of the company in the open market. On 5/6/2026, he completed an open-market purchase of 1,562 shares of Aclarion common stock at a price of $3.30 per share. After this transaction, his direct holdings total 1,563 common shares.
Aclarion, Inc. director William Wesemann bought shares of the company in the open market. On 5/6/2026, he completed an open-market purchase of 1,562 shares of Aclarion common stock at a price of $3.30 per share. After this transaction, his direct holdings total 1,563 common shares.
Aclarion, Inc. has authorized a stock repurchase program of up to $2.5 million of its outstanding common shares. The company expects to carry out repurchases over the next 12 months, using methods such as open market purchases, block trades, privately negotiated deals, and 10b5-1 plans.
Aclarion plans to fund the program with existing cash and cash equivalents. As of March 31, 2026, it held approximately $19.0 million in cash and cash equivalents, which management believes is sufficient to support operations through key milestones, including the initial milestone of the CLARITY randomized trial.
Management describes the buyback as part of disciplined capital allocation and states they believe the current share price does not fully reflect the company’s Nociscan platform and long-term growth opportunity. The program is flexible and may be suspended, modified, or discontinued at any time.
Aclarion, Inc. has authorized a stock repurchase program of up to $2.5 million of its outstanding common shares. The company expects to carry out repurchases over the next 12 months, using methods such as open market purchases, block trades, privately negotiated deals, and 10b5-1 plans.
Aclarion plans to fund the program with existing cash and cash equivalents. As of March 31, 2026, it held approximately $19.0 million in cash and cash equivalents, which management believes is sufficient to support operations through key milestones, including the initial milestone of the CLARITY randomized trial.
Management describes the buyback as part of disciplined capital allocation and states they believe the current share price does not fully reflect the company’s Nociscan platform and long-term growth opportunity. The program is flexible and may be suspended, modified, or discontinued at any time.
Gregory A. Gould, Chief Financial Officer of Aclarion, Inc. (ticker shown as ACON), reported an option grant on a Form 4 filed 09/03/2025 for a transaction dated 09/02/2025. The filing shows an award of 17,000 stock options with an exercise price of $7.15. The options are reported as directly held and the underlying common stock amount is 17,000 shares.
The filing explains the vesting schedule: 25% vests on September 2, 2026, and the remaining 75% vests in 36 equal monthly installments thereafter. The derivative shows an expiration or related date of 09/02/2035 in the table and the reporting person signed the form on 09/03/2025.
Gregory A. Gould, who is listed as an officer (CFO) and director of Aclarion, Inc. (ACON), filed an initial Form 3 reporting event dated 09/02/2025. The filing states that Mr. Gould does not beneficially own any securities of the issuer at the time of the report. The form provides his business address in Broomfield, Colorado, and is signed 09/03/2025.
Aclarion, Inc. disclosed the appointment of Gregory A. Gould as Chief Financial Officer with an employment agreement effective September 1, 2025. The filing references an employment agreement and a related press release dated September 3, 2025, indicating the company has completed the executive hiring step and made public communications about the change. The notice identifies the role, the named officer, and the cited exhibits but does not include compensation details, background biography, or forward guidance.
Aclarion, Inc. reported results for the quarter ended June 30, 2025. Cash and cash equivalents were $12,850,657 (including $11,949,908 in money market funds), which management believes funds operations into the third quarter of 2026. Revenue grew to $19,319 in Q2 2025 (up 76% year-over-year) and $38,309 for the six months (up 82%), driven by increased NOCISCAN report volume in the U.K. Q2 gross profit was $5,140, but operating expenses rose to $1.74 million, producing a Q2 net loss of $1.60 million and a six-month net loss of $3.64 million. In H1 2025 the company raised approximately $20.1 million via a public unit offering, two registered direct offerings and warrant exercises. Corporate actions included two 2025 reverse stock splits and the $1,213,590 redemption of Series B preferred stock. The company recorded a $687,500 settlement in March 2025. Readers should consult the full notes for detailed terms of warrants, preferred conversions, and cash assumptions.